Read More

ADC Therapeutics Announced Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA in Europe and Select International Territories; ADC Therapeutics is Eligible to Receive Up to $435M, Including Milestones

ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan.

ADCT

Read More

KeyBanc Re-rated These Vertical Software, FinTech Stocks Based On Current Economic Backdrop: Read To Know

KeyBanc analyst Josh Beck noted that rates on the 10-year fell below 1% before quickly expanding by ~2%, which coincided with a dramatic digital adoption surge, triggering a rapid rise and subsequent fall for high-growth, long-duration tech assets. 

AVDX